GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD Inflamm Bowel Dis. 2024 Oct 22:izae250. doi: 10.1093/ibd/izae250. Online ahead of print. Irving Levine 1, Shaina Sekhri 1, William Schreiber-Stainthorp 2, Brandon Locke 3, Olivia Delau 4, Mohamed Elhawary 4, Krutika Pandit 5, Xucong Meng 5, Jordan Axelrad 4 |
Author information 1Division of Gastroenterology, Department of Medicine, NYU Langone Health, Manhattan, NY 10016, USA. 2Department of Medicine, NYU Langone Health, Manhattan, NY 10016, USA. 3New York University, Manhattan, NY 10003, USA. 4Inflammatory Bowel Disease Center, NYU Langone Health, New York, NY 10016, USA. 5NYU Grossman School of Medicine, Manhattan, NY 10016, USA. Abstract Background: In patients with inflammatory bowel disease (IBD), multimorbidity with obesity and type 2 diabetes is common and increasing. Glucagon-like peptide 1 (GLP-1) receptor agonists are increasingly being prescribed for patients with IBD, yet their impact on patients with IBD is largely unknown. We aimed to assess the impact of GLP-1 receptor agonists on the course of IBD. Methods: We identified all IBD patients prescribed GLP-1 receptor agonists at a large academic healthcare network between 2009 and 2023. We analyzed demographics and IBD characteristics in the year pre- and post-GLP-1 receptor agonist prescription and matched them to non-IBD controls. Our primary outcome was IBD exacerbation in the year following GLP-1 receptor agonist initiation, measured as a composite of IBD-related hospitalization, corticosteroid prescription, medication escalation or changes, or IBD-related surgery. Secondary outcomes included change in metabolic risk factors. Results: Overall, 224 patients met inclusion criteria. At GLP-1 receptor agonist initiation, the median age was 54 years, 63% were female, 77% were White, and median BMI was 33.2 kg/m2. Compared to the 12-month period prior to GLP-1 receptor agonist initiation, in the 12 months post-GLP-1 receptor agonist initiation, there was no change in rates of IBD exacerbation, IBD-related hospitalization, steroids prescription, medication escalation or changes, or IBD-related surgery. There was a significant decrease in BMI in the year following GLP-1 receptor agonist initiation (median BMI 33.5 vs 31.6 kg/m2, P < .01), with rates of decrease comparable to non-IBD matched controls. Conclusions: In patients with IBD, GLP-1 receptor agonists are effective for weight loss and associated with few episodes of disease exacerbation. |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.